Viewpoint News & Awards

June 22, 2019 | Anaheim, CA.

Viewpoint Co-Founder and Chief Science Officer Michael K. Schultz, PhD led the Department of Energy Lead-212 User Meeting at the 2019 Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting, held in Anaheim, CA. This event is a forum for the radiopharmaceutical community to come together and share respective success and challenges of introducing alpha-particle radionuclide therapy for cancer using lead-212. Dr. Schultz has consecutively led this event at the SNMMI annual meeting for the past three years. 

Get in Touch

Join Our Mailing List

Enter your email address below for occasional updates from Viewpoint Molecular Targeting

©2021, Viewpoint Molecular Targeting™.  All Rights Reserved.